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quantitative real-time PCr (QrT-PCr) and single mrNA 
molecule counting on the Nanostring nCounter platform. 
Nanostring proved to be highly sensitive, specific, and lin-
ear, with sensitivity comparable or exceeding that of rNA 
seq. We evaluated the prognostic significance and molec-
ular correlates of rTK rearrangements. egFrvIII was 
only detectable in tumors with focal amplification of the 
gene. Moreover, we found that egFrvIII expression was 
not prognostic of poor outcome and that neither recurrent 
copy number alterations nor global changes in gene expres-
sion differentiate egFrvIII-positive tumors from tumors 
with amplification of wild-type egFr. The wide range of 
expression of mutant alleles and co-expression of multi-
ple egFr variants suggests that quantitative rNA-based 
clinical assays will be important for assessing the relative 
expression of intragenic deletions as therapeutic targets 
and/or candidate biomarkers. To this end, we demonstrate 
the performance of the Nanostring assay in rNA derived 
Abstract Intragenic deletion is the most common form of 
activating mutation among receptor tyrosine kinases (rTK) 
in glioblastoma. However, these events are not detected by 
conventional DNA sequencing methods commonly utilized 
for tumor genotyping. To comprehensively assess the fre-
quency, distribution, and expression levels of common rTK 
deletion mutants in glioblastoma, we analyzed rNA from a 
set of 192 glioblastoma samples from The Cancer genome 
Atlas for the expression of egFrvIII, egFrvII, egFrvV 
(carboxyl-terminal deletion), and PDgFrAΔ8,9. These 
mutations were detected in 24, 1.6, 4.7, and 1.6 % of cases, 
respectively. Overall, 29 % (55/189) of glioblastomas 
expressed at least one rTK intragenic deletion transcript in 
this panel. For egFrvIII, samples were analyzed by both 
e. r. Kastenhuber and J. T. Huse have contributed equally to this 
work.
Electronic supplementary material The online version of this 
article (doi:10.1007/s00401-013-1217-3) contains supplementary 
material, which is available to authorized users.
e. r. Kastenhuber · J. T. Huse · Y. Suehara · M. ladanyi 
Department of Pathology, Memorial Sloan-Kettering Cancer 
Center, New York, NY, USA
J. T. Huse · J. Zhang · M. ladanyi · C. W. Brennan 
Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, 
New York, NY, USA
S. H. Berman · A. Pedraza · Y. Suehara · A. Heguy · M. ladanyi · 
C. W. Brennan (*) 
Human Oncology and Pathogenesis Program,  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
e-mail: cbrennan@mskcc.org
A. Viale · M. Cavatore 
genomics Core Facility, Memorial Sloan-Kettering Cancer 
Center, New York, NY, USA
A. Heguy 
geoffrey Beene Translational Oncology Core Facility,  
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
N. Szerlip 
Department of Neurosurgery, Wayne State University Medical 
School, Detroit, MI, USA
C. W. Brennan 
Department of Neurosurgery, Memorial Sloan-Kettering Cancer 
Center, New York, NY, USA
748 Acta Neuropathol (2014) 127:747–759
1 3
from routinely collected formalin-fixed paraffin-embedded 
tissue.
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Introduction
large-scale genomic characterization has confirmed strik-
ing heterogeneity underlying the molecular landscape of 
gBM and has catalogued a spectrum of tumor suppressors 
and oncogenes affected by deletion, amplification, muta-
tion, and/or rearrangement. Alterations of receptor tyrosine 
kinases (rTKs) are especially prevalent in gBM. rTKs 
are a class of mitogenic signaling proteins including epi-
dermal growth factor receptor (egFr), platelet-derived 
growth factor receptor-α (PDgFrA) and MeT, that are 
widely implicated in human oncogenesis. Indeed, high-
level amplification of the EGFR locus represents the single 
most common genomic abnormality in gBM, occurring in 
~45 % of all cases, and PDGFRA and MET are also fre-
quently amplified, in 10–15 % and ~4 % of gBMs, respec-
tively [5, 10, 31, 43]. Moreover, these amplification events 
have been associated with specific disease subclasses, 
defined by transcriptional and proteomic signatures [4, 37, 
45], implying that molecular distinctions within gBM are, 
to some extent, mechanistically grounded in dysregulated 
rTK signaling.
rTK amplification in gBM is often associated with 
intragenic deletions and gene rearrangements, as well as 
extracellular domain point mutations [5, 23, 44]. As many 
as half of egFr-amplified gBMs have been reported to 
express the variant III mutation (vIII), a 287-amino acid 
in-frame deletion of exons 2–7 in the egFr extracellu-
lar domain (eCD) [42]. The resulting protein constitu-
tively signals in a ligand-independent manner by forming 
homodimers or heterodimeric complexes with either wild-
type egFr or other erbB family members [12]. egFrvIII 
primarily stimulates the oncogenic PI3K/AKT pathway 
[17, 29], but is also known to interact with the adapter pro-
teins Shc and grb2, thereby activating rAS/MAPK sign-
aling [39]. Additionally, egFrvIII-expressing tumor cells 
may exert paracrine influence on their neighbors by secret-
ing either microvesicles containing the protein itself [1] or 
mitogenic cytokines like Il-6 and lIF [19]. Other cancer-
relevant functionalities ascribed to egFrvIII include eva-
sion of apoptosis [30], tumor cell invasion [22], angiogen-
esis [50] and stem cell self-renewal [16].
A number of additional egFr intragenic deletions have 
been identified. Some, like egFr vI (exon 1–7 deletion) 
and egFr vIV (intracellular domain microdeletion), are 
rare [6, 9, 38, 48], while others like egFrvII and egFrvV 
are marginally more common, each accounting for more 
than 10 % of all gBM-associated egFr mutations [20, 28, 
32]. The vII deletion includes a small 83-amino acid stretch 
within the egFr eCD [47], while egFrvV involves a 
C-terminal truncation that ablates the majority of the pro-
tein’s intracellular domain, a region responsible for mediat-
ing internalization and degradation [6, 9, 48]. Functional 
analyses of both mutations have been complicated by their 
frequent co-occurrence with egFrvIII [10]. However, 
recent work has demonstrated that egFrvV is itself capable 
of transformation both in vitro and in mouse xenografts [7].
Intragenic rearrangements in PDGFRA have also been 
described in gBM. Similar to their counterparts in egFr, 
these appear to largely occur in the context of high-level 
genomic amplification. An in-frame deletion in the Ig-like, 
extracellular domain of PDgFrA (PDgFrAΔ8,9) has been 
detected in up to 40 % of PDgFrA-amplified cases and 
results in constitutive kinase activation in vitro [21, 36]. Cases 
of C-terminal truncation (PDgFrAΔCt) have also been 
reported, although defined functional consequences remain 
to be established [40]. Moreover, it has yet to be determined 
how these mutations correlate with other oncogenic and sub-
class-defining molecular abnormalities in gBM.
The prevalence of rTK intragenic deletions, particularly 
egFrvIII, in significant subsets of gBM has made them 
both attractive therapeutic targets for immunotherapeutic 
approaches and promising predictive biomarkers for phar-
macologic receptor inhibitors [26, 35]. In this context, there 
remains a need to effectively detect and quantify egFr vIII 
and related abnormalities in rTKs to power more detailed 
functional analysis and therapeutic trial stratification. Cur-
rently, most clinical labs that assess egFrvIII status do so 
using non-quantitative techniques such as immunohisto-
chemistry (IHC) and/or reverse transcription-polymerase 
chain reaction (rT-PCr) for the mutant transcript. Other 
intragenic deletions in egFr and those of PDgFrA are not 
routinely measured as a component of standard patient care.
To determine the frequency and molecular context of 
common rTK intragenic deletions in gBM, we profiled 
192 tumors from TCgA for egFrvIII using both quanti-
tative reverse transcriptase PCr (QrT-PCr) and a novel 
approach based on Nanostring nCounter technology. The 
latter platform was also employed to assess egFrvII, 
egFrvV, and PDgFrAΔ8,9, in the same sample set. We 
demonstrate that intragenic deletion mutants, particularly 
egFrvIII, comprise highly variable proportions of total 
rTK expression in a given tumor, ranging from the major-
ity mrNA species to only a minor component. Paired with 
orthogonal profiling data from TCgA, these findings now 
represent the most comprehensive tumor-based assessment 
of rTK deletion mutation in gBM to date, and provide a 
resource for integrated molecular analysis. Moreover, we 
find that Nanostring-based analysis performs robustly 
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from formalin-fixed paraffin-embedded tissue (FFPe), thus 
empowering investigation and characterization of a wide 
dynamic range of expression of egFrvIII and other dele-
tion mutations in the context of clinical trials.
Methods
Human tissue and rNA extraction
rNA from TCgA samples was allocated from the Bio-
specimen Core resource as 3 μg aliquots and sent to the 
MSKCC TCgA Pilot Phase Cancer genome Characteriza-
tion Center (CgCC). TCgA sample collection and rNA 
extraction followed published protocols [5, 44]. An addi-
tional independent tumor sample set was used to confirm 
the fidelity of the assay applied to FFPe, including surgical 
specimens collected at Memorial Sloan-Kettering Cancer 
Center and frozen. All patients consented prior to surgery 
under a protocol approved by the institution’s Institutional 
review Board. Patient-matched FFPe tissue for com-
parison was obtained following routine processing by the 
Department of Pathology and diagnostic confirmation by a 
neuropathologist (J.T.H.). rNA was extracted from either 
crushed frozen tissue or 3–8 10 μm slides using the rNe-
asy Mini kit (Qiagen).
Quantitative reverse transcriptase PCr
From the TCgA sample set, 275 cases with available rNA 
were interrogated for relative expression of wild-type 
egFr and egFrvIII by rT-PCr. 400 ng of total rNA was 
reverse-transcribed using the Thermoscript rT-PCr system 
(Invitrogen) at 52 °C for 1 h. 20 ng of resultant cDNA was 
used in a Q-PCr reaction using an 7500 real-Time PCr 
System (Applied Biosystems) and custom-designed TaqMan 
gene expression Assays (egFrvIII Forward primer: 
5′CgggCTCTggAggAAAAg3′; egFrvIII reverse 
primer: 5′AggCCCTTCgCACTTCTTAC3′; egFrvIII 
internal primer: 5′gTgACAgATCACggCTCgTg3′; total 
egFr: pre-designed TaqMan ABI gene expression Assays 
Hs01076076_m1). Primers were chosen based on their 
ability to span the most 3′ exon–exon junction. Amplifica-
tion was carried for 40 cycles (95 °C for 15 s, 60 °C for 
1 min). To calculate the efficiency of the PCr reaction, and 
to assess the sensitivity of each assay, we also performed 
a six-point standard curve (5, 1.7, 0.56, 0.19, 0.062, and 
0.021 ng). Triplicates CT values were averaged, amounts of 
target were interpolated from the standard curves and nor-
malized to TBP (TATA box binding protein pre-designed 
TaqMan ABI gene expression Assays Hs00427620_m1). 
efficiency of each reaction was determined from the stand-
ard curve of a serially diluted sample using the equation: 
efficiency = 10(−1/slope) − 1, where slope is fitted to CT vs. 
log10 (concentration). relative quantities of TBP, egFr 
and egFrvIII were calculated from each CT[i] based on 
the reaction efficiencies and minimum CTs from the stand-
ard dilution curves (CTmax) according to the formula: Quan-
tity = (1 + efficiency)(CTmax−CT). All reactions were per-
formed in triplicate. Samples were rejected if multiple TBP 
replicates failed to cross threshold in <36 cycles or if the 
median absolute deviation of quantified TBP across repli-
cates was greater than 25 % (5 of 275 samples). The relative 
quantities of egFr and egFrvIII were normalized with 
respect to TBP.
Nanostring
The nCounter Analysis System (Nanostring Technologies, 
Seattle, WA) allows for multiplexed digital mrNA profil-
ing without amplification or generation of cDNA [13]. 
Briefly, mrNA is hybridized with pairs of ~50 bp probes 
complementary to each target. The reporter probe is tagged 
by a target-specific code of four fluorescent reporters at 
seven positions along a phage DNA backbone. The capture 
probe is used for immobilization on a slide and once ori-
ented in an electric field; bound reporters are counted and 
annotated. A custom probe set was designed as detailed 
in Supplemental Table S1. Total rNA (150–300 ng) was 
hybridized with the codeset probes and loaded into the 
nCounter prep station. The samples were quantified using 
the nCounter Digital Analyzer.
The Nanostring platform includes negative control 
probes (not complementary to any endogenous mrNA) to 
assess background noise associated with the fluorescent 
barcode optical recognition system. To ensure that all sam-
ples were within the optimal range of probe density for 
image analysis, we confirmed that there was no systemic 
increase in negative control counts as a function of total 
number of counts recorded per sample. raw probe counts 
were normalized to a panel of 8 control genes (B2M, 
B4gAlT1, ClTC, e2F4, gAPDH, POlr2A, SDHA, and 
TBP) by taking the ratios of each gene’s counts per sample 
to the average across all samples and scaling by the median 
of these ratios in each sample. This normalization factor 
was also applied to the negative control probes counts. A 
detection threshold was defined for each sample as five 
times the mean of the negative control probe normalized 
counts. Of 192 samples run, three cases (TCgA-02-0021, 
TCgA-12-0827 and TCgA-19-1386) were excluded from 
analysis as outliers with low expression of the 8 con-
trol genes (possibly representing under-loading or poor 
hybridization).
C-terminal deletion mutation was inferred by the occur-
rence of relative underexpression (undercounting) of 
the exon 28 probe versus the exon 19 probe. The normal 
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(wild-type) linear relationship of counts between these two 
probes was determined by a linear model fit to the central 
90 % of the data. This model was then applied to the entire 
dataset to identify cases with outlier C-terminal underex-
pression. These cases fell into in two groups: intermediate 
expression of the truncation mutant (<60 % of expected 
c-terminal counts), or high expression (<10 %).
rNA and DNA sequence analysis
rNA and DNA sequencing data (BAM files mapped to 
hg19) were obtained from TCgA through CgHub. rNA 
sequencing was analyzed to tabulate egFr and PDgFrA 
exon junctions as described [5]. Briefly, counts were made 
of all egFr and PDgFrA reads spanning exon–exon junc-
tions and all paired exonic reads with gaps spanning one 
or more introns. Only reads with perfect alignment scores 
(CIgAr score) were considered. To account for 3′ bias in 
rNA sequence representation, mutant junction counts were 
compared with counts of normal junctions at the 3′ exon. 
For example, egFrvIII expression was defined by count-
ing reads with e1–e8 junctions and comparing to the count 
of reads with “wild type” e7–e8 junctions. egFrvII was 
defined by e13–e16 vs. wild-type e15–e16. PDgFrA 
D89 was defined by e7–e10 vs. wild-type e9–e10. A junc-
tion was counted only if seen in more than one read. exome 
DNA sequence data for 291 tumors were analyzed to deter-
mine read coverage within the egFr gene in two regions: 
exons 2–7 (the egFrvIII deleted region) and exons 8–22 
(spanning the transmembrane and kinase domain regions). 
The normal ratio of counts between regions was deter-
mined by linear regression fit of the middle 90 % of ratios. 
This model was applied to normalize the ratios and allow 
accurate estimation of relative copy number of exons 2–7 
vs. exons 8–22.
DNA copy number analysis
TCgA level 3 copy number data (normalized and seg-
mented) were downloaded from the TgCA Data Portal for 
Affymetrix SNP6.0 data (Broad Institute). Copy number 
was inferred for exon 6 (within the 2–7 deletion) and com-
pared with that of exon 19 (kinase domain region) to iden-
tify relative deletion. level 2 data (normalized) for Agilent 
244k aCgH data (MSKCC) were downloaded parsed into 
to subsets of probe values: probes residing between the 
midpoint of intron 1 and the endpoint of exon 7 were taken 
as representing the deleted region in vIII and these log2 
ratios were compared to those of probes residing from the 
start of exon 8 through exon 21 using Student’s t test. A p 
value of 0.05 was taken as significant (uncorrected for mul-
tiple testing). CNA focality, a measure of how many genes 
are included in simple and complex aberrations, was scored 
for egFr in each sample using a genome Topography 
Scan method previously described (gTS [5, 43, 49]).
Statistical analysis
Data analyses were performed in r (http://cran. 
r-project.org/). A prospective panel of hypotheses regarding 
the difference between egFr-amplified/egFrvIII+ and 
egFr-amplified/egFrvIII− were evaluated by Fisher’s 
exact test for discrete events and by a two-sided student’s 
t test for continuous variables and p values were adjusted 
by FDr. In all cases, the egFrvIII-high and low posi-
tives (egFrvIII in >1 % of egFr transcripts), along with 
egFr-high positives alone (egFrvIII in >10 % of egFr 
transcripts), were independently compared with wild-type 
egFr-amplified tumors. exploratory searches for differen-
tially expressed genes and mirNAs were performed using 
empirical Bayes analysis within the linear Models for 
Microarray Analysis package implemented in r [41].
Results
QrT-PCr and Nanostring profiling reveal a wide range 
of egFrvIII expression in egFr-amplified gBM
To assess the frequency and extent of egFrvIII mutations 
in gBM, we developed two independent methods for quan-
titative measurement of egFrvIII. After initial validation, 
these assays were applied to mrNA extracted from gBM 
samples as part of the initial gBM TCgA Pilot Project [5, 
44]. Specifically, a TaqMan-based qrT-PCr approach was 
compared to a Nanostring nCounter assay (NS), each tar-
geting both the exon 1–8 junctional region of egFrvIII 
(e1–8) and the egFr kinase domain (KD) as well as 
select control genes (see “Methods”). After normalization, 
egFrvIII expression (e1–8) was compared to total egFr-
encoding mrNA (KD). The expression of egFrvIII was 
categorized using NS as absent (<fivefold above mean neg-
ative control counts, see “Methods”) or present as a frac-
tion of overall egFr: <1 % (black), 1–10 % (orange) or 
≥10 % (red). As shown in Fig. 1a, b, both platforms dem-
onstrated a similar pattern of expression of egFr over-
all (KD) and of the vIII variant ranging over three orders 
of magnitude. egFrvIII measures were well correlated 
across platforms (Fig. 1c). Notably, this correlation was 
seen even among cases with NS counts below the negative 
detection threshold (open circles, Fig. 1c) suggesting either 
detection of very low levels of egFrvIII expression or a 
component of non-specific hybridization common to both 
platforms. The estimated ratio of egFrvIII to total egFr 
was highly concordant between platforms (Fig. 1d). linear-
ity of the Nanostring readout was confirmed by performing 
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serial dilution of an egFr vIII-high positive sample into 
an egFr vIII-negative sample, yielding near-perfect cor-
relation (R2 >0.99) (Fig. 1e–g).
Validation of the Nanostring assay with rNA-seq
To more definitively ascertain the performance of the 
Nanostring assay, we correlated our findings with transcrip-
tome sequencing (rNA-seq) data from TCgA, available 
for 61 samples in our study set (47 with NS data). We found 
near universal agreement between “positive” status on the 
Nanostring platform and the presence of bridging rNA-
seq reads spanning the exon 1–8 breakpoint in egFrvIII 
(Fig. 2a, colored dots). Only one discordant sample, judged 
positive by Nanostring but lacking confirmed junctional 
reads by rNA-seq, was identified (Fig. 2a, arrow). How-
ever, this absence of reads is within sampling error based 
on the rNA-seq coverage (225×) given transcribed allelic 
fraction of vIII at 1.6 % as estimated by NS. rT-PCr con-
firmed that this discrepant case was egFrvIII+, with a low 
transcribed allelic fraction (~9 %). Overall, the coverage of 
counts by NS was much higher than reads by rNA-seq. 
Among the 47 samples with both rNA sequencing and NS 
data, the mean coverage of egFr by rNA-seq was 450× 
compared to a mean of 12,000 counts in the NS data. Over-
all, 60 % of samples, comprised largely of tumors without 
high-level egFr amplification, did not reach 100× cover-
age at the egFr locus by rNA-seq, precluding the defini-
tive detection of a minor (<1 %) transcript population.
To estimate a lower bound for egFrvIII expression 
among samples with relatively low egFr expression, we 
pooled all rNA-seq reads from 25 cases with NS counts 
for egFr <10,000 and egFrvIII counts up to 100 (box, 
Fig. 2a). Among a total of 853 reads of egFr, the vIII 
Fig. 1  expression of egFrvIII as a fraction of total egFr is quanti-
fied by Nanostring assay and qrT-PCr in 189 gBMs. a expression 
of egFrvIII (exon 1–8 junctional probe) is shown as a function of 
egFr kinase domain (KD), determined by normalized Nanostring 
(NS) counts. expression levels are classified as high [red mutation 
in >10 % transcribed allelic fraction (TAF)], intermediate (orange 
1–10 % TAF), marginal (black <1 % TAF) or negative (open circles). 
These color assignments are carried through panels b–d. b Correla-
tion of egFrvIII expression between NS and qrT-PCr. Normal-
ized expression levels are plotted for egFrvIII and KD from the 
Taqman assay (see “Methods”). Samples are colored according to 
NS expression classification from Fig. 1a. c Cross-platform correla-
tion of egFrvIII epression, NS vs. qrT-PCr. d Cross-platform cor-
relation of egFrvIII as a fraction of total egFr, NS vs. qrT-PCr. 
e experimental design of dilution experiment to establish linearity 
of the Nanostring assay. A sample with high relative expression of 
egFrvIII was diluted with a sample negative for egFrvIII expres-
sion, maintaining a constant 250 ng of total rNA in each reaction. f 
Counts of egFrvIII and egFr KD as a function of diluted fraction 
of egFrvIII-containing sample
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junction was not seen once, suggesting that any expression 
of egFrvIII in this population is <1 % at most (95 % con-
fidence interval is 0–0.43 %).
Because egFrvIII mutation is associated with genomic 
deletion of exons 2–7, we sought to determine whether 
assessment of this deletion by DNA copy number data could 
serve as a surrogate for rNA-based determination. TCgA 
exome sequencing data for 291 gBMs were analyzed to 
determine the read coverage within the egFr exon 2–7 
interval and a control interval from exon 8–22 (see “Meth-
ods”). egFrvIII expression was then compared for 157 cases 
for which rNA-seq data were also available. As shown in 
Fig. 2b, all samples that expressed egFrvIII mrNA showed 
evidence of a relative loss of exons 2–7 at the DNA level, 
and samples with the greatest copy number change showed 
the highest vIII expression levels. exon 2–7 deletion inferred 
from exome coverage was able to predict vIII expression with 
at least 80 % sensitivity at 95 % specificity (Supplemental 
Fig. S1a). In the TCgA dataset, exome coverage was a more 
sensitive detector of intragenic deletion than microarray data, 
specifically the Affymetrix SNP6.0 and Agilent array-CgH 
platforms, although all DNA measures lacked the sensitivity 
of mrNA assays (Supplemental Fig. S1b, c).
Nanostring profiling effectively detects egFrvII, 
egFrvV, and PDgFrAΔ8,9 in small subsets 
of rTK-amplified gBM
Using analogous approaches to that employed for egFr 
vIII, we developed Nanostring assays for the detec-
tion of egFr vII and PDgFrAΔ8,9 based on their 
specific breakpoint regions. Additionally, we sought to 
measure egFr vV transcript by including a probe set in 
our Nanostring panel directed against the C-terminal of 
egFr (egFr C-term), allowing detection based on the 
count ratio of the C-term and kinase domains.
Applying these assays to the TCgA cohort revealed dis-
tinct clusters of outliers characterized by high-level expres-
sion of mutant transcript (Fig. 3a–c). For egFrvII, we 
detected three samples expressing the mutant allele over a 
threshold of 2 % of total egFr counts (and with egFrvII 
count >5× negative controls). rNA-seq data were available 
for two of the three cases and confirmed expression of the 
vII junction in both (Supplemental Fig. S2). Although NS 
data demonstrated a strong correlation between total egFr 
expression and a low level (<1 %) of egFrvII counts, 
rNA-seq failed to confirm the vII junction in most of these 
cases (Supplemental Fig. S2).
For egFr vV, we stratified positive samples into “high” 
and “low” on the basis of percent composition of C-termi-
nal deleted transcript (Fig. 3b, see “Methods”). Five cases, 
accounting for 2.6 % of all tumors and 6 % of the egFr-
amplified subset, exhibited marked C-terminal loss (>90 % 
egFr mutated; Fig. 3b, red). Interestingly, a recent TCgA 
report examining genomic alterations in egFr by micro-
array-based copy number analysis demonstrated that these 
same five samples exhibit profoundly reduced levels of the 
egFr C-terminal exon [7]. Moreover, our data also indicated 
lower expression levels of the C-terminal deletion transcript 
in four previously unidentified samples (Fig. 3b, orange). 
Taken together, 4.7 % of cases overall (10.8 % of egFr-
amplified cases) showed evidence of C-terminal truncation 
Fig. 2  Comparison with orthogonal platforms a egFrvIII vs. total 
egFr as determined by Nanostring is plotted. egFrvIII expres-
sion was determined independently from TCgA rNA-seq analy-
sis (rNAS). Red denotes cases with >10 % TAF by rNAS, green 
1–10 % and blue <1 %. Black circles filled with gray mark cases 
where no rNAS reads identified egFrvIII; empty circles mark cases 
for which rNA-seq data were unavailable. b egFrvIII expression 
was compared with genomic loss of egFr exons 2–7 in 157 cases 
for which both rNA and DNA (exome) sequencing data were avail-
able. Samples are ordered by the magnitude of exon 2–7 deletion 
inferred from DNA seq coverage. expression was determined by the 
ratio of VIII junction rPKM to total egFr
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in a significant proportion of egFr transcript. In addition 
to truncations of the C-terminus, deletion mutations affect-
ing exons 25–27 have been identified by analysis of rNA 
sequencing data in the TCgA dataset [5]. These intragenic 
deletions do not include the terminal exon and therefore 
would not be detected by the NS panel used in this study.
High-level PDgFrAΔ8,9 expression was identified in 
three samples, representing 1.6 % of all tumors and 17.6 % 
of the PDgFrA-amplified subset (Fig. 3b). None of the 
high-expressing cases had rNA-seq data available. How-
ever, analysis of the remaining cases identified that a low 
level of the Δ8,9 junction could occasionally be detected as 
a minor fraction of expressed PDgFrA [5]. The complete 
dataset of Nanostring, QrT-PCr and rNA-seq results is 
available at the public portal (https://tcga-data.nci.nih.gov/
docs/publications/gbm_2013/).
Analysis of paired specimens suggests robust performance 
of Nanostring-based intragenic deletion profiling in FFPe 
specimens
FFPe tissue blocks remain the standard for clinical sample 
processing in medical centers, despite suboptimal preserva-
tion of biomaterials like nucleic acids. To assess the perfor-
mance of our Nanostring assay in FFPe samples, we utilized 
an independent cohort of patient-matched fresh-frozen and 
FFPe specimens (N = 45). Total rNA extracted from FFPe 
and fresh-frozen samples was analyzed for rTK intragenic 
deletions in both egFr and PDgFrA. We found strong 
correlations between FFPe and fresh-frozen rNA in the 
levels of total egFr (Spearman rho = 0.883, p < 2.2e-16, 
Fig. 4a) and egFrvIII (Spearman rho = 0.444, p = 0.002, 
Fig. 4b). For egFrvIII and other deletion mutations, the 
majority of cases expressed levels below background. Con-
sequently, the variance of noise at near-zero counts reduced 
correlations for the population as a whole. The NS assay 
also appeared to perform well in the context of presumptive 
clinical decision-making. Specifically, a binary classifier 
for egFrvIII (negative/borderline versus positive) applied 
to results from FFPe material demonstrated 100 % sensi-
tivity and 94 % specificity (Fig. 4c). Moreover, measured 
egFrvIII counts in the two identified “false positives” were 
in the low-positive range, indicating superior performance 
in samples containing high levels of egFrvIII transcript. 
As confirmation of the specificity of the Nanostring assay 
for egFrvIII in gliomas, no positive results were observed 
in rNAs from 269 non-glioma samples (not from TCgA) 
including 97 lung adenocarcinomas, 23 ductal breast car-
cinomas, 36 colon carcinomas, 21 thyroid carcinomas, 25 
osteosarcomas, 12 chondrosarcomas, 18 cholangiocarcino-
mas, and 37 samples of non-neoplastic lung tissue (Y. Sue-
hara, M. ladanyi, unpublished data). Concordance between 
FFPe and frozen was comparable for the other deletion 
mutation probes (Supplemental Fig. S3).
Consistent with extensive prior literature [12, 42, 51], we 
found a tight association between egFrvIII mutation and 
high-level egFr amplification in our sample set defined by 
aCgH log2 ratio >2 (Fig. 5a). Only two cases with high-
level egFrvIII expression demonstrated log2 ratios below 
2 (TCgA-06-0156 and TCgA-08-0360). However, exam-
ination of aCgH data for both cases revealed focal CNA 
of the egFr locus in a pattern consistent with high-level 
amplification within a subpopulation of cells, as confirmed 
by FISH for one sample (TCgA-06-0156) [43]. We con-
firmed this observation by evaluating all 116 cases with 
both rNA-seq and aCgH data available (Supplemental Fig. 
S4). egFrvIII transcript was detected by sequencing in 
38 of the 64 cases with focal egFr amplification (59 %). 
No egFrvIII transcript was found among the subset of 52 
unamplified cases, while the WT junction was read a total 
Fig. 3  Assessment of egFrvII, egFrvV and PDgFrAΔ8,9 using 
Nanostring probes. a Probes targeting the aberrant junctions char-
acterizing egFrvII expression levels are classified as positive (red 
mutation in >2 % TAF), or not detected (open circles). b egFrvV 
(C-terminal deletion) is detected by relative under-representa-
tion of exon 28 vs. exon 19 harboring the kinase domain (KD). c 
PDgFrAΔ8,9 expression is stratified as in Fig. 1a
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of 1,789 times (95 % CI for egFrvIII 0–0.21 %). These 
results establish that gBMs rarely if ever express high lev-
els of egFrvIII in the absence of focal amplification of 
the locus. Additionally, there is no evidence of promiscu-
ous low-level expression that one might expect if egFrvIII 
were the result of common splicing variation.
egFrvIII does not independently correlate with specific 
molecular and/or clinical features within egFr-amplified 
gBM
egFr amplification and egFrvIII expression were both 
associated with the classical transcriptional subclass 
Fig. 4  Performance of Nanostring assay applied to suboptimal 
material. Counts of egFr-WT (a) and egFrvIII (b) are correlated 
between patient-matched samples maintained by optimal, flash-fro-
zen, and suboptimal, versus formalin-fixed paraffin-embedded sam-
ples (FFPE), preservation methods. c Concordance of NS assay as a 
binary classifier from FFPe and frozen material
Fig. 5  genomic and clinical 
correlates of egFrvIII expres-
sion. a Significant egFrvIII 
expression is exclusively found 
in tumors with amplification of 
egFr. NS counts of egFrvIII 
expression are plotted with 
respect to kinase domain 
counts. Blue circles denote 
samples with egFr point muta-
tion. Red denotes tumors with 
high-level amplification of the 
egFr locus (aCgH log2 ratio 
>2). For two samples with high 
egFrvIII expression, but log2 
ratios below 2 (red arrows), 
aCgH demonstrates focal CNA 
in a pattern consistent with 
high-level gene amplification 
in a subpopulation of cells (and 
demonstrated by FISH for one 
of the two cases [43]). b Asso-
ciation between egFr status 
and transcriptomal subclass. 
c Overall survival of patients 
stratified by egFrvIII status. 
d Overall survival of patients 
stratified by egFrvIII status 
excluding g-CIMP tumors, 
which are known to have a more 
favorable prognosis
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(Fig. 5b). However, this association was not indepen-
dently significant for egFrvIII. Moreover, egFrvIII 
positivity at any level was not predictive for overall 
survival in gBM (Fig. 5c). An apparent overall differ-
ence of long-term survivors disappears after excluding 
patients with the distinct phenotype of gBM Cpg island 
hypermethylation (g-CIMP [34]) (Fig. 5d). Cox pro-
portional hazards regression models fit either egFrvIII 
counts, egFr-WT counts, or egFrvIII/egFr ratio 
revealed no significant prognostic value for any of these 
parameters.
In a further effort to identify molecular features dis-
tinguishing egFrvIII-mutant tumors from their wild-
type egFr-amplified counterparts, we utilized copy 
number, gene expression, and histopathological data for 
our TCgA sample set [5]. We first prospectively tested a 
limited set of selected molecular and histopathological 
parameters including small cell histology or pseudopali-
sading necrosis; deletion/mutation of TP53, NF1, PTEN, 
CDKN2A, CDKN2C, and RB1; amplification of CDK4/6; 
mrNA expression of Il6 or lIF, MMP13 and BCl-Xl. 
This demonstrated no statistically significant differences 
between egFrvIIIHI (n = 20) and egFrvIII-negative 
tumors (n = 37) within the egFr-amplified subset 
(Supplemental Table S2). We then tested all TCgA-
measured variables using empirical Bayesian analysis 
and found no specific copy number events or mrNAs, 
mirNAs, or proteins whose differential expression 
between egFrvIII-positive, and wild-type egFr-
amplified tumors reached statistical significance. Simi-
larly, no scored histopathological features were found to 
delineate mutant and wild-type samples by Chi-squared 
analysis.
Molecular and clinical features of gBMs harboring other 
rTK intragenic deletions
We screened other available molecular data to identify fea-
tures that might be correlated with expression of egFrvII, 
egFrvV, and PDgFrAΔ8,9. As expected, PDgFrAΔ8,9 
was seen at high levels only in the context of high-level 
PDgFrA amplification and its presence exclusively within 
the proneural expression subclass (Fig. 6; Supplemental 
Fig. S5c). Similarly, both egFrvII and egFrvV-posi-
tive tumors were invariably amplified for egFr (Fig. 6). 
Somewhat surprisingly, we found that the three egFrvII-
expressing tumors were all assigned to the mesenchymal 
expression subgroup (Supplemental Fig. S5a). By contrast, 
egFr vV-positive tumors, particularly those exhibiting 
strong positivity, were primarily designated as classical, 
although mesenchymal and neural classifications were also 
seen, primarily for lower expressers (Supplemental Fig. 
S5b).
Detailed analysis of gene expression data revealed that, 
unlike for egFrvIII, egFrvII positivity correlated with a 
defined gene signature relative to wild-type egFr-ampli-
fied tumors. In total, we observed 27 genes with statisti-
cally significant upregulation in egFrvII tumors (Sup-
plemental Table S3). Of these, 26/27 genes were similarly 
upregulated in mesenchymal tumors versus all others with 
two genes also upregulated in the setting of egFr ampli-
fication, likely reflecting the transcriptional and genomic 
features of the three egFrvII-positive tumors. gene ontol-
ogy (gO) analysis revealed significant correlations between 
the egFrvII gene signature and chemokine activity, signal 
transduction, cellular locomotion (Supplemental Table S4). 
We did not identify genes or expression signatures similarly 
Fig. 6  Molecular context of egFr alterations in gBM. From top to bottom egFr mrNA expression, DNA copy number, deletion mutation 
expression, transcriptomal and methylation subclass are reported for each sample
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associated with either egFr vV or PDgFrAΔ8,9 posi-
tivity relative to wild-type receptor-amplified tumors, nor 
were specific mirNAs or copy number events correlated 
with any of the three deletion mutants. Moreover, consist-
ent with earlier work demonstrating the frequent co-occur-
rence of egFr vII and vV with vIII [10], we found that 
all egFr vII-positive tumors and 44 % (4/9) of egFr vV-
positive tumors in our sample set also expressed high levels 
of egFr vIII (Fig. 6). Finally, overall survival was not sig-
nificantly different between either egFr vII or vV-mutant 
tumors and all others (Supplemental Fig. S6a-S6b). And 
while Kaplan–Meier analysis identified poorer outcomes 
for PDgFrAΔ8,9 tumors (p = 0.0257), sample size limits 
the robustness of this finding (Supplemental Fig. S6c).
Discussion
The Cancer genome Atlas gBM initiative has recently 
completed analysis of a molecularly and clinically anno-
tated dataset of unprecedented detail for over 500 tumors 
[5]. This project was initiated in 2006, before the advent of 
high-throughput DNA and rNA sequencing technologies. 
As a result, the initial TCgA marker paper in 2008 had 
no direct measure of intragenic deletion mutations despite 
these being the most common forms of rTK activation in 
gBM [44]. Our study aims to provide this annotation for 
189 TCgA tumors, quantified by Nanostring and verified 
for egFrvIII quantitatively by rT-PCr. As technology 
has advanced, TCgA has subsequently performed rNA 
sequencing for 164 of the most recent cases, 47 overlap-
ping our NS dataset. Together, the NS and rNA-seq data 
provide a quantitative annotation of common rTK dele-
tion variants for 306 tumors. The ability to cross-reference 
expression levels of egFrvIII and other rTK deletions 
against the clinical and detailed molecular data in TCgA 
provides a valuable resource to better understand the 
molecular context in which these mutations are found.
We found no prognostic significance of egFrvIII 
expression in the primary gBMs comprising TCgAs data-
set. This is consistent with some prior studies performed 
on independent datasets [2, 15, 24]. Our global analysis of 
molecular correlates of egFrvIII and other deletion muta-
tions revealed that, for the most part, tumors with these 
mutations were also not distinguished by specific molecu-
lar features compared to their wild-type rTK-amplified 
counterparts. This analysis does not imply that egFrvIII 
expression has no molecular effects, but rather that detect-
ing these effects in the TCgA data will require prospective 
testing of select hypotheses. The TCgA dataset also does 
not reflect differences in subcellular localization, post-
translational modification, or degradation of egFr pro-
tein, any or all of which might be impacted distinctly by 
vIII mutation [7, 14, 25]. Nonetheless, the global similar-
ity of egFr-amplified tumors, whether egFrvIII posi-
tive or negative, suggests that common features are shared 
by gBMs with egFr activation by any means, and that 
neomorphic functions specific to egFrvIII may not be 
strongly influential on the tumor phenotypes measured 
here. In contrast, egFrvII-expressing gBMs do appear 
to have an expression signature distinct from most other 
egFr-amplified tumors. It is likely that this finding reflects 
the association of vII mutation with mesenchymal rather 
than classical transcriptional subclass, as 26/27 egFrvII 
signature genes (96 %) were also associated with non-vII-
expressing mesenchymal gBMs in the same analysis.
Because rTK mutations are typically associated with 
gene amplification in gBM, there can be a wide range of 
expression of mutant and wild-type alleles [10], and these 
levels may vary tumor-to-tumor and even cell-to-cell [19, 
33]. earlier work has shown that multiple mutations can 
affect a single egFr allele [10]. recent analysis of TCgA 
rNA-seq data revealed that multiple egFr deletion and 
point mutations were often expressed in the same tumor at 
different allelic frequencies [5]. We observed a high rate of 
co-occurrence between different egFr deletion mutants in 
our sample set—100 % of egFrvII and 44 % of egFrvV-
positive tumors also harbored egFrvIII. The biological sig-
nificance of multiple coincident egFr deletion mutations 
in the same tumor remains unclear. Interestingly, some evi-
dence supports the possibility of functional heterodimeriza-
tion involving mutant and wild-type receptors, which may 
play a driving role in the maintenance of egFrvIII as a 
minority species in a transformed cell [11, 25].
In addition to providing a molecular annotation resource, 
this report describes a transcript-based quantitative assess-
ment of egFrvIII, along with other deletion mutants oper-
ative from a relatively small amount of biomaterial. Our 
Nanostring-based assay exhibited notable linearity even at 
low levels of transcript expression and performed well in 
the context of FFPe starting material. This latter finding, 
consistent with a number of prior studies, likely reflects 
the absence of PCr in the Nanostring workflow. Indeed, 
such signal amplification can accentuate systematic error 
in quantitative measurements, particularly in the context 
of compromised starting material. Methods for the routine 
detection of rTK deletion mutants like egFrvIII from sur-
gical biopsy material remain poorly standardized and non-
quantitative. Immunohistochemistry and/or rT-PCr are the 
predominant assays used in the clinical setting, with results 
typically interpreted in a binary fashion as either “positive” 
or “negative”. While such readouts are practical for certain 
applications and are currently less expensive, they do not 
accurately capture the molecular and cellular heterogeneity 
known to characterize gBM, nor are they readily quanti-
fiable. Moreover, recent analysis has shown that multiple 
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egFr point and deletion mutations can be expressed in the 
same tumor at different allelic frequencies [5].
Overall, our findings agree with prior literature, both 
in the proportion of cases where Nanostring was sug-
gestive of egFrvIII—24 % of total and 54 % of egFr-
amplified—as well as the proportion of high-level express-
ers (10.6 % overall) [3, 51]. These figures include cases 
in which egFrvIII was detected in <1 % of egFr tran-
scripts, where the biological significance and contribu-
tion of technical noise is unknown. Available rNA-seq 
data from overlapping TCgA samples provided strong 
cross-validation, as detectable reads for egFrvIII were 
present in all but one of the samples designated >1 % 
by Nanostring. Similar correlations were observed for 
egFrvII, egFrvV, and PDgFrA Δ8,9, albeit on fewer 
samples. The higher sensitivity of the Nanostring assay to 
detect mutant transcripts at low expression levels may be 
related to better coverage depth. In all cases, Nanostring 
provided markedly higher read counts than rNA-seq (typ-
ically 50- to 100-fold greater). Next-generation sequenc-
ing costs can only be expected to fall in the coming years, 
enabling higher read counts routinely. Nevertheless, the 
limited tissue specimens available in the clinical setting 
may be insufficient to supply the microgram quantities of 
rNA typically required for transcriptome sequencing, and 
a significant proportion of clinical material is FFPe. Thus, 
assay platforms that are both cost- and resource-effective 
will continue play central roles in clinical management. 
Additionally, the ability of the Nanostring nCounter to 
assess up to 800 mrNAs simultaneously, while not com-
prehensive, should allow the multiplexing of rTK dele-
tion mutants with a number of other transcripts and gene 
expression signatures of interest without increasing the 
required biomaterial.
rTK deletion mutants, along with their wild-type recep-
tors, remain therapeutic targets of considerable potential 
for gBM. The lack of encouraging clinical results with 
rTK inhibition thus far may reflect, in part, inadequate 
drug penetration, lack of molecular stratification in clini-
cal trials and signaling feedback mechanisms [8, 18, 27]. 
Cellular and molecular heterogeneity involving wild-type 
and mutant rTK composition, as we observed in this study, 
likely complicates strategies to effectively inhibit onco-
genic signaling. Indeed, investigations carried out in vitro 
and in human patients indicate that the inhibitor sensitivity 
profiles of wild-type egFr and egFrvIII are distinct [46]. 
In this respect, our findings and those of others support the 
notion that a successful therapeutic strategy will require the 
effective inhibition of both mutant and wild-type receptor 
at concentrations achievable in the target tissue. Indeed, 
incomplete targeting of egFr isoforms could simply drive 
tumor evolution toward a cellular population expressing an 
untargeted (resistant) variant. For loci that are commonly 
amplified in gBM, “quantitative genotyping” of the ampli-
cons and their contained mutations may be a requirement to 
unambiguously establish their value as predictive and prog-
nostic markers, particularly if established pathogenic muta-
tions exist as minority species. Consequently, methodolo-
gies such as those described in this report may prove vitally 
important to standard clinical practice.
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